Epizyme (EPZM) Misses Q3 EPS by 3c

Epizyme (NASDAQ: EPZM) reported Q3 EPS of ($0.58), $0.03 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $8.2 million versus the consensus estimate of $7 million.

For earnings history and earnings-related data on Epizyme (EPZM) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c